Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.110352 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.110352 33129009!7577270!33129009     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Med+Hypotheses 2020 ; 145 (ä): 110352 Nephropedia Template TP {{tp|p=33129009|t=2020. Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis |pdf=|usr=}}{{33129009}} gab.com Text Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=33129009 #FOAvip The Coronavirus Diseases-2019 (COVID-19) pandemic leads many researchers around the world to study the SARS-CoV-s2 infection and pathology to find a treatment for it. This generates a massive production of papers including pre-clinical, clinical and revisions but till now no specific treatment were identified. Meanwhile, like other coronavirus infections, COVID-19 leads to the cytokine storm syndrome resulting in hyperinflammation, exacerbated immune response and multiple organ dysfunctions indicating that drugs that modulate this response, as glucocorticoids could be a treatment option. However glucocorticoids have several side effects or usage limitations. In this sense a drug with anti-inflammatory effects and capable to reduce inflammation but with less after-effects could be a powerful tool to combat COVID-19. Thus the Ac2-26 Mimetic Peptide of Annexin A1 emerges as a possible therapy. The peptide has many anti-inflammatory effects described including the reduction of interleukin (IL)-6, one of the main mediators of cytokine storm syndrome. Therefore the hypothesis to use the Ac2-26 peptide to treat severe COVID-19 will be highlighted in this paper. Twit Text FOAVip Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=33129009 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33129009 #FOAvip English Wikipedia <ref>{{Cite pmid|33129009}}</ref> Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypothesis #MMPMID33129009 Bonavita AG Med Hypotheses 2020[Dec]; 145 (ä): 110352 PMID33129009show ga The Coronavirus Diseases-2019 (COVID-19) pandemic leads many researchers around the world to study the SARS-CoV-s2 infection and pathology to find a treatment for it. This generates a massive production of papers including pre-clinical, clinical and revisions but till now no specific treatment were identified. Meanwhile, like other coronavirus infections, COVID-19 leads to the cytokine storm syndrome resulting in hyperinflammation, exacerbated immune response and multiple organ dysfunctions indicating that drugs that modulate this response, as glucocorticoids could be a treatment option. However glucocorticoids have several side effects or usage limitations. In this sense a drug with anti-inflammatory effects and capable to reduce inflammation but with less after-effects could be a powerful tool to combat COVID-19. Thus the Ac2-26 Mimetic Peptide of Annexin A1 emerges as a possible therapy. The peptide has many anti-inflammatory effects described including the reduction of interleukin (IL)-6, one of the main mediators of cytokine storm syndrome. Therefore the hypothesis to use the Ac2-26 peptide to treat severe COVID-19 will be highlighted in this paper. |*COVID-19 Drug Treatment[MESH] |Annexin A1/*chemistry[MESH] |Anti-Inflammatory Agents/chemistry[MESH] |COVID-19/*immunology/*therapy[MESH] |Cytokines/metabolism[MESH] |Humans[MESH] |Inflammation[MESH] |Interleukin-6/metabolism[MESH] |Models, Theoretical[MESH] |Peptides/*chemistry[MESH]Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: A hypot(epmc).pdf DeepDyve Pubget Overpricing